Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV-ONE: Single-dose vs two-dose 9-valent HPV vaccination in men
jRCTs031240746Recruiting
- Sponsor
- National Center for Global Health and Medicine
- Start
- Apr 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, anal intraepithelial neoplasia (AIN) and oropharyngeal cancer (2 arms), sponsored by National Center for Global Health and Medicine. Primary endpoint: HPV16 IgG seropositivity rate at Week 96. Started Apr 2025; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionanal intraepithelial neoplasia (AIN)oropharyngeal cancer
Beyond the preview
Go deeper on jRCTs031240746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240746.